3886 (3886) Fair Value & Analysis

Healthcare · Market cap HK$1.4B

3 3886 3886 · HK

PriceHK$0.2070

Fair ValueHK$0.0600

Upside-71.0%

Quality59/100

Watch 3886 for free — get notified when fair value or trend changes. Watch for free

Evidence: Medium Range HK$0.0400 – HK$0.0800

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price −2.9% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.2070 – HK$0.3025 · fair‑value band HK$0.0400 – HK$0.0800 · the HK$0.2070 price screens above the HK$0.0600 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

3886 (3886) currently trades at HK$0.2070, while our model-based Fair Value estimate is HK$0.0600 — implying the stock looks roughly 71.0% overvalued today. We read business quality at 59/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, 3886 generated revenue of HK$1.8B at a net margin of 0.8%. Revenue declined 3.8% year over year. It earns a return on equity of 1.9%. The balance sheet holds a net cash position of HK$1.0B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$1.8B

Revenue growth (YoY) -3.8%

Net margin 0.8%

Return on equity 1.9%

Free cash flow HK$129M FY2025

Operating margin 4.6%

More key figures

Dividend yield 0.9%

EPS growth (YoY) +159%

Net cash HK$1.0B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

3886 reported revenue of HK$1.8B in FY2025 versus HK$1.5B in FY2021, a compound +4.7%/yr. Reported net income was HK$14.4M in FY2025, compounding −10.1%/yr from FY2021.

Revenue +4.7%/yr

FY21 HK$1.5B

FY22 HK$1.5B

FY23 HK$1.8B

FY24 HK$1.8B

FY25 HK$1.8B

Net income −10.1%/yr

FY21 HK$22.0M

FY22 HK$15.3M

FY23 −HK$194M

FY24 −HK$204M

FY25 HK$14.4M

Is 3886 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
HCA Healthcare, Inc H1CA34	R$97.60	R$115.75	+19%
Fresenius SE FSNUY	$11.47	$8.55	-25%
5225 5225	8.71 MYR	4.87 MYR	-44%
IHHHF IHHHF	$1.71	$1.17	-32%
Tenet Healthcare Corporation THC	$164.77	$280.85	+70%
Rede D'Or São Luiz S.A RDOR3	R$32.50	R$46.04	+42%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 3886 (3886) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.0600 versus a price of HK$0.2070 — about −71% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 3886?

Our model-based fair value for 3886 is HK$0.0600 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.2070.

What is the quality score of 3886?

3886 has a Quality Score of 59/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 3886 (3886)?

3886 reported trailing-twelve-month revenue of about HK$1.8B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 3886?

The net profit margin of 3886 is about 0.8%, meaning it keeps roughly 0.8% of revenue as net income. Based on the latest reported figures.

Does 3886 pay a dividend?

3886 currently shows a dividend yield of about 0.93% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.